Cetera Investment Advisers Sells 4,227 Shares of TransMedics Group, Inc. $TMDX

Cetera Investment Advisers lowered its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 51.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,033 shares of the company’s stock after selling 4,227 shares during the period. Cetera Investment Advisers’ holdings in TransMedics Group were worth $271,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in TMDX. Braidwell LP acquired a new stake in TransMedics Group in the 4th quarter worth approximately $57,493,000. Mackenzie Financial Corp raised its position in shares of TransMedics Group by 73.0% in the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock valued at $51,635,000 after purchasing an additional 349,403 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of TransMedics Group by 1,565.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company’s stock worth $16,820,000 after buying an additional 253,624 shares during the last quarter. Avidity Partners Management LP lifted its stake in shares of TransMedics Group by 597.1% in the fourth quarter. Avidity Partners Management LP now owns 192,400 shares of the company’s stock worth $11,996,000 after buying an additional 164,800 shares during the last quarter. Finally, Frontier Capital Management Co. LLC bought a new stake in shares of TransMedics Group during the 4th quarter worth $9,415,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Down 0.7%

Shares of TMDX stock opened at $121.88 on Thursday. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. The stock has a fifty day moving average price of $122.60 and a 200 day moving average price of $100.65. The stock has a market cap of $4.15 billion, a P/E ratio of 63.15 and a beta of 2.09.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. The firm had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. Analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Morgan Stanley lifted their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Piper Sandler reiterated an “overweight” rating and issued a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Oppenheimer raised their target price on TransMedics Group from $130.00 to $150.00 and gave the company an “outperform” rating in a report on Tuesday, June 17th. Finally, Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $123.00.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 5,000 shares of the stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total value of $632,250.00. Following the completion of the transaction, the director owned 2,866 shares of the company’s stock, valued at $362,405.70. This represents a 63.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David Weill sold 732 shares of TransMedics Group stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total value of $90,680.16. Following the sale, the director directly owned 12,134 shares in the company, valued at $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,418 shares of company stock valued at $818,833 over the last quarter. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.